Compare VMAR & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VMAR | VRAX |
|---|---|---|
| Founded | 1995 | 2013 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0M | 972.3K |
| IPO Year | 2020 | 2021 |
| Metric | VMAR | VRAX |
|---|---|---|
| Price | $7.05 | $1.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.0K | ★ 152.5K |
| Earning Date | 11-27-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $29.11 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.10 |
| 52 Week High | $12.96 | $13.19 |
| Indicator | VMAR | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 47.39 | 28.53 |
| Support Level | $6.50 | $0.15 |
| Resistance Level | $8.35 | $2.92 |
| Average True Range (ATR) | 0.64 | 0.15 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 42.47 | 21.07 |
Vision Marine Technologies Inc designs and manufactures electric outboard powertrain systems, power boats, related technology, and rents electric boats. Its models include Bruce 22, Fantail 217, VX Electric Pontoon, Volt 180, Phantom, and others. The company provides goods and services for the recreational boating market and focuses on electric outboard powertrain systems, electric power boats, and the renting of electric boats through its subsidiary. It sells boats, parts, and accessories and offers services related to recreational boating, including boats with internal combustion engines and electric propulsion. The company operates in two reportable segments, the sale of electric boats and the rental of electric boats, and generates a substantial portion of its revenue from the USA.
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.